Plant viral vectors have great potential for rapid production of important pharmaceutical proteins. High-yield production, however, of hetero-oligomeric proteins that require the expression and assembly of two or more protein subunits often is problematic due to the competing nature of viral vectors derived from the same virus. Researchers at the...

Protein microarrays have the potential to revolutionize proteomics research for vaccine development, drug discovery, and diagnosis. However, this potential is far from being realized mainly due to technical complexity of protein array fabrication and uncertainties about the functionality and integrity of proteins once immobilized onto a solid surface....

More than 170 million people worldwide are chronic carriers of Hepatitis C Virus (HCV), but there is no therapeutic vaccine currently available for treating this infection. Persistent HCV infection results in chronic active hepatitis which may lead to progressive liver disease. Current treatment strategies are expensive, have substantial side effects,...

Modified vaccinia virus can be used as a vector to deliver genes encoding proteins for therapeutic and vaccine applications. Researchers at the Biodesign Institute of Arizona State University and their collaborators at the Massachusetts Institute of Technology have developed a form of vaccinia virus with genetic modifications that decrease the risk...

Vaccinia Virus Vectors and Methods to Prevent the Pathology Caused by Infectious Agents Modified vaccinia virus can be used as a vector to deliver genes encoding proteins for therapeutic and vaccine applications. Researchers at the Biodesign Institute of Arizona State University and their collaborators at the Massachusetts Institute of Technology...